DDInter1042 DDInter1269
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
Nateglinide {u} (Compound) resembles {v} (Compound) Amphetamine
Nateglinide {u} (Compound) resembles {v} (Compound) Ramipril
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enalapril
Nateglinide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Nateglinide {u} (Compound) binds {v} (Gene) ABCC8
Nateglinide {u} (Compound) is included by {v} (Pharmacologic Class) Potassium Channel Antagonists
Nateglinide {u} (Compound) causes {v} (Side Effect) Dermatitis
Nateglinide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Nateglinide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylcellulose
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Nateglinide (Compound) resembles Amphetamine (Compound)
Nateglinide (Compound) resembles Ramipril (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Enalapril
Nateglinide (Compound) treats type 2 diabetes mellitus (Disease)
Nateglinide (Compound) binds ABCC8 (Gene)
Nateglinide (Compound) is included by Potassium Channel Antagonists (Pharmacologic Class)
Nateglinide (Compound) causes Dermatitis (Side Effect)
Nateglinide may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Nateglinide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib